Abstract
Parkinson’s disease is one of the most common neurodegenerative disorders in elder people and the leucine-rich repeat kinase 2 (LRRK2) is a promising target for its pharmacological treatment. In this paper, QSAR models for identification of potential inhibitors of LRRK2 protein are designed by using an in house chemical library and several machine learning methods. The applied methodology works in two steps: first, several alternative subsets of molecular descriptors relevant for characterizing LRRK2 inhibitors are identified by a feature selection software tool; secondly, QSAR models are inferred by using these subsets and three different methods for supervised learning. The performance of all these QSAR models are assessed by traditional metrics and the best models are analyzed in statistical and physicochemical terms.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B., Stoessl, A.J., Pfeiffer, R.F., Patenge, N., Carbajal, I.C., Vieregge, P., Asmus, F., Muller-Myhsok, B., Dickson, D.W., Meitinger, T., Strom, T.M., Wszolek, Z.K., Gasser, T.: Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601–607 (2004)
Gilligan, P.J.: Inhibitors of leucine-rich repeat kinase 2 (LRRK2): progress and promise for the treatment of Parkinson’s disease. Curr. Top. Med. Chem. 15, 927–938 (2015)
Estrada, A.A., Sweeney, Z.K.: Chemical biology of Leucine-Rich repeat Kinase 2 (LRRK2) inhibitors. J. Med. Chem. 58, 6733–6746 (2015)
Cookson, M.R.: LRRK2 pathways leading to neurodegeneration. Curr. Neurol. Neurosci. Rep. 15, 42 (2015)
Smith, W.W., Pei, Z., Jiang, H., Moore, D.J., Liang, Y., West, A.B., Dawson, V.L., Dawson, T.M., Ross, C.A.: Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl. Acad. Sci. U.S.A. 102, 18676–18681 (2005)
Volpicelli-Daley, L.A., Abdelmotilib, H., Liu, Z., Stoyka, L., Daher, J.P., Milnerwood, A.J., Unni, V.K., Hirst, W.D., Yue, Z., Zhao, H.T., Fraser, K., Kennedy, R.E., West, A.B.: G2019S-LRRK2 expression augments alpha-synuclein sequestration into inclusions in neurons. J. Neurosci. 36, 7415–7427 (2016)
Lima, A., Philot, E., Trossini, G., Scott, L., Maltarollo, V., Honorio, K.: Use of machine learning approaches for novel drug discovery. Expert Opin. Drug Discov. 11, 225–239 (2016)
Kahn, I., Lomaka, A., Karelson, M.: Topological fingerprints as an aid in finding structural patterns for LRRK2 inhibition. Mol. Inform. 33, 269–275 (2014)
Pourbasheer, E., Aalizadeh, R.: 3D-QSAR and molecular docking study of LRRK2 kinase inhibitors by CoMFA and CoMSIA methods. SAR QSAR Environ. Res. 27, 385–407 (2016)
Salado, I.G., Zaldivar-Diez, J., Sebastian-Perez, V., Li, L., Geiger, L., Gonzalez, S., Campillo, N.E., Gil, C., Morales, A.V., Perez, D.I., Martinez, A.: Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents. Eur. J. Med. Chem. 138, 328–342 (2017)
Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J.: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3–26 (2001)
Eklund, M., Norinder, U., Boyer, S., Carlsson, L.: Choosing feature selection and learning algorithms in QSAR. J. Chem. Inf. Model. 54, 837–843 (2014)
Soto, A.J., Martínez, M.J., Cecchini, R.L., Vazquez, G.E., Ponzoni, I.: DELPHOS: computational tool for selection of relevant descriptor subsets in ADMET prediction. In: 1st International Meeting of Pharmaceutical Sciences (2010)
Frank, E., Hall, M.A., Witten, I.H.: The WEKA Workbench. Online Appendix for “Data Mining: Practical Machine Learning Tools and Techniques”, 4th edn. Morgan Kaufmann, Massachusetts (2016)
Acknowledgments
This work is kindly supported by CONICET, grant PIP 112-2012-0100471 and UNS, grants PGI 24/N042 and PGI 24/ZM17. We also acknowledge MECD, VSP grant FPU15/01465 and Banco Santander for VSP fellowship AY21/17-D-27 in the “Becas Iberoamerica-Santander Investigación” program.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this paper
Cite this paper
Sebastián-Pérez, V., Martínez, M.J., Gil, C., Campillo, N.E., Martínez, A., Ponzoni, I. (2019). QSAR Modelling for Drug Discovery: Predicting the Activity of LRRK2 Inhibitors for Parkinson’s Disease Using Cheminformatics Approaches. In: Fdez-Riverola, F., Mohamad, M., Rocha, M., De Paz, J., González, P. (eds) Practical Applications of Computational Biology and Bioinformatics, 12th International Conference. PACBB2018 2018. Advances in Intelligent Systems and Computing, vol 803. Springer, Cham. https://doi.org/10.1007/978-3-319-98702-6_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-98702-6_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-98701-9
Online ISBN: 978-3-319-98702-6
eBook Packages: Intelligent Technologies and RoboticsIntelligent Technologies and Robotics (R0)